Search hospitals

>

New York

>

Stony Brook

Stony Brook University Cancer Center

Claim this profile

Stony Brook, New York 11794

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Cancer

Conducts research for Leukemia

Conducts research for Lymphoma

59 reported clinical trials

5 medical researchers

Photo of Stony Brook University Cancer Center in Stony BrookPhoto of Stony Brook University Cancer Center in Stony BrookPhoto of Stony Brook University Cancer Center in Stony Brook

Summary

Stony Brook University Cancer Center is a medical facility located in Stony Brook, New York. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Leukemia, Lymphoma and other specialties. Stony Brook University Cancer Center is involved with conducting 59 clinical trials across 96 conditions. There are 5 research doctors associated with this hospital, such as Minsig Choi, Amna Sher, Alexander N. Slade, and Alison Stopeck, MD.

Area of expertise

1

Breast Cancer

Global Leader

Stony Brook University Cancer Center has run 17 trials for Breast Cancer. Some of their research focus areas include:

Stage III
Stage IV
HER2 negative
2

Lung Cancer

Global Leader

Stony Brook University Cancer Center has run 15 trials for Lung Cancer. Some of their research focus areas include:

metastatic
locally advanced
Stage IV

Top PIs

Clinical Trials running at Stony Brook University Cancer Center

Lung Cancer

Breast Cancer

Lung Adenocarcinoma

Non-Hodgkin's Lymphoma

Colon Cancer

Thyroid Nodule

Cancer

Non-Small Cell Lung Cancer

Parkinson's disease

Skin Cancer

Image of trial facility.

Pembrolizumab + Sacituzumab Tirumotecan

for Lung Cancer

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).

Recruiting

2 awards

Phase 3

Image of trial facility.

Sacituzumab Tirumotecan vs Standard Therapy

for Lung Cancer

The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study are that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to progression-free survival (PFS) and overall survival (OS).

Recruiting

2 awards

Phase 3

2 criteria

Image of trial facility.

Yoga + Mindfulness

for Cancer Survivors

Cancer survivors can experience health issues that cause chronic illness and lower quality of life. Yoga is a well-known holistic approach to health and overall well-being. Mindfulness has many benefits, including improved focus and less stress. This study aims to evaluate if yoga and/or mindfulness has a positive effect on cancer survivors social, emotional and physical well-being as well as their epigenetics. Epigenetics is how the environment can effect your genes; not by changing our DNA, but by turning genes on or off.

Recruiting

1 award

N/A

2 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Stony Brook University Cancer Center?